Cargando…

Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics, and Therapeutics

Detalles Bibliográficos
Autores principales:	Zhan, Fenghuang, Zangari, Maurizio, Qiu, Lugui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427090/ https://www.ncbi.nlm.nih.gov/pubmed/26000289 http://dx.doi.org/10.1155/2015/384575

Ejemplares similares

Drug Resistance in Hematological Malignancies
por: Auberger, Patrick, et al.
Publicado: (2020)

Targeting p53 by small molecules in hematological malignancies
por: Saha, Manujendra N, et al.
Publicado: (2013)

Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders
por: Găman, Amelia Maria
Publicado: (2023)

Nursing in patients with hematological malignancies
por: Geres, Hana, et al.
Publicado: (2020)

Immune Therapies for Hematologic Malignancies
por: Olnes, Matthew J.
Publicado: (2021)

Immune Microenvironment in Hematologic Malignancies
por: Arandi, Nargess, et al.
Publicado: (2023)

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

The Role of Exosomes in the Progression and Therapeutic Resistance of Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2022)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

The premier statistical report of hematologic malignancies in Korea
por: Kim, Hee-Je
Publicado: (2012)

Centrosome Defects in Hematological Malignancies: Molecular Mechanisms and Therapeutic Insights
por: Hu, Mingzheng, et al.
Publicado: (2022)

Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview
por: Barbato, Alessandro, et al.
Publicado: (2020)

Therapeutic Benefits of Selenium in Hematological Malignancies
por: Ehudin, Melanie A., et al.
Publicado: (2022)

Therapeutic Advances in Immunotherapies for Hematological Malignancies
por: Nogami, Ayako, et al.
Publicado: (2022)

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance
por: Shi, Lei, et al.
Publicado: (2010)

Accuracy of diagnosis and individualization of treatment: the way of treating hematologic malignancies
por: Liu, Dai-Hong
Publicado: (2020)

Preface of the Special Issue “COVID-19 Infection and Hematological Malignancies”
por: Chen, Mingyi, et al.
Publicado: (2022)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

Genetics of Bladder Malignant Tumors in Childhood
por: Zangari, Andrea, et al.
Publicado: (2016)

New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents
por: Harvey, R. Donald
Publicado: (2018)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies
por: Izuegbuna, Ogochukwu O.
Publicado: (2022)

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies
por: Khalili, Saeed, et al.
Publicado: (2023)

Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice
por: Ma, Haiqing, et al.
Publicado: (2015)

Chromosomal aberrations in hematological malignancies: A guide to the identification of novel oncogenes
por: Vundinti, Babu Rao, et al.
Publicado: (2011)

CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011)

For older adults with hematologic malignancies, a comprehensive geriatric assessment matters
por: Cordoba, Raul
Publicado: (2022)

Drug Design and Development for Rare Hematologic Diseases
por: Fattizzo, Bruno, et al.
Publicado: (2023)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Mechanism of action of lenalidomide in hematological malignancies
por: Kotla, Venumadhav, et al.
Publicado: (2009)

Patients with hematological malignancies admitted to intensive care units: new challenges for the intensivist
por: Torres, Viviane Bogado Leite, et al.
Publicado: (2015)

Genetic Predisposition to Hematologic Malignancies in Childhood and Adolescence
por: Fabozzi, Francesco, et al.
Publicado: (2023)

An interview with Dan L. Longo, Section Editor of the Malignant hematological diseases section
por: Longo, Dan L
Publicado: (2013)

Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies
por: Wiestner, Adrian
Publicado: (2022)

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
por: Jiang, Bo, et al.
Publicado: (2021)

2019–2020 Drug Updates in Hematologic Malignancies
por: Finnes, Heidi D.
Publicado: (2021)

2018–2019 Drug Updates in Hematologic Malignancies
por: Held, Lauren
Publicado: (2020)

2020–2021 Drug Updates in Hematologic Malignancies
por: Hanna, Kirollos
Publicado: (2022)

2021–2022 Drug Updates in Hematologic Malignancies
por: Tobin, Jenni
Publicado: (2023)

Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies
por: Sorrentino, Claudia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g1889ti7kae6mmbpnilbipj30c